-
It’s all about delivery-antibodies improve nanoparticle delivery of therapeutic nucleic acids
Time of Update: 2021-11-05
Image: Antibody-guided Nanoparticle Delivery SystemSource: Baylor College of MedicineStudies have shown that some nucleic acids, such as messenger RNA (mRNA), DNA and related molecules, can effectively treat diseases in a laboratory environment.
-
the therapeutic window of antibody-conjugated drugs (ADC) at the 33rd International Conference on Molecular Targets and Cancer Therapy
Time of Update: 2021-11-05
Based on the innovative technology platform, Pufang Bio has developed a series of product pipelines composed of drug candidates targeting solid tumor targets.
-
The first domestic allergic asthma therapeutic antibody new drug submitted to NDA!
Time of Update: 2021-11-04
If omalizumab is approved by the National Food and Drug Administration, it is expected to become the first monoclonal antibody asthma therapy developed by a Chinese company and marketed in China .
-
The past, present and future of therapeutic antibody engineering
Time of Update: 2021-11-03
One disadvantage of this technology is that due to antigen processing and imaging of mouse genetic factors regulated by B cells, the monoclonal antibodies obtained may not be as specific as the antibodies naturally produced in humans.
-
Roche's ophthalmic bispecific antibody has a therapeutic effect comparable to aflibercept for longer treatment intervals
Time of Update: 2021-08-10
In terms of secondary endpoints, more than half of the patients in the faricimab personalized administration group in the two studies maintained a 16-week interval between treatments in the first year .
-
TG Therapeutics' third-generation CD20 monoclonal antibody listing application was accepted by the U.S. FDA | Yimai Meng broke the news
Time of Update: 2021-06-01
There are B lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, transmembrane 4-domain subfamily A member 1, etc. The protein function may be involved in regulating B cell activation and proliferation
-
China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States
Time of Update: 2021-04-28
The institute stated that this indicates that the safety and effectiveness of new coronavirus-specific antibody drugs with China's independent intellectual property rights have been recognized by the world.
-
China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States
Time of Update: 2021-03-27
The institute stated that this indicates that the safety and effectiveness of new coronavirus-specific antibody drugs with China's independent intellectual property rights have been recognized by the world.
-
China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States
Time of Update: 2021-03-25
The institute stated that this indicates that the safety and effectiveness of new coronavirus-specific antibody drugs with China's independent intellectual property rights have been recognized by the world.
-
"Pharmaceutical Speed Reading Society" China's new crown therapeutic antibody new drug
Time of Update: 2021-03-25
On March 15th, Jingfeng Pharmaceutical issued an announcement stating that its holding subsidiary had recently received a notice from the FDA that the abbreviated new drug application for Lincomycin Hydrochloride Injection has been approved.
-
-Junshi Bio's new crown therapeutic antibody new drug combination treatment method for emergency use in the EU
Time of Update: 2021-03-21
The picture shows the monoclonal antibody combination therapy drugs, the red is LY-CoV016 jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Junshi Biotechnology, and the black is LY-CoV555.
-
China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States
Time of Update: 2021-03-18
style="vertical-align: inherit;"> In October 2020, Eli Lilly Pharmaceuticals disclosed the interim data of a phase II clinical trial of a combination therapy of LY-CoV555 and LY-CoV016, which showed that when
-
Junshi Bio cooperates with Lilly Pharmaceuticals to develop preventive and therapeutic antibody therapies
Time of Update: 2021-03-01
May 4, Regency Bio and Lilly Pharmaceuticals announced that they had reached an agreement to jointly develop potential preventive and therapeutic antibody therapies for new coronary pneumonia caused by the new SARS-CoV-2 coronavirus.
-
Hengrui Pharmaceutical PD-1 antibody two first-line therapeutic adaptation phase 3 clinical up to the main research...
Time of Update: 2021-01-05
On December 16th Henri Pharmaceuticals announced that the innovative drug, Carelli pearl monoantigen (Erika), had reached the end of two Phase 3 clinical studies: one for first-line treatment of advanced esophageal cancer with combined yew alcohol
-
Hengrui Pharmaceutical PD-1 antibody two first-line therapeutic adaptation phase 3 clinical end of the main study
Time of Update: 2020-12-23
Karelli pearl monoantigen is an humanized PD-1 monoclonal antibody independently developed by Hengrui Pharmaceuticals and has intellectual property rights, which can bind to human PD-1 receptors and block the PD-1/PD-L1 path, restore the body's anti
-
The team of the Chinese Academy of Sciences has developed therapeutic antibodies for new coronary
Time of Update: 2020-11-26
of the new application for clinical trials, 5 has been officially approved by the State Drug Administration, its Phase I clinical trials will be in healthy people for safety and dose testing. This is the world's first non-human primate
-
Science: Reveals the mechanism by which therapeutic antibodies bind to human CD20.
Time of Update: 2020-09-07
August 18, 2020 /--- Since the late 1990s, immunotherapy has been the first line of treatment to combat lymphoma, using synthetic antibodies to prevent the proliferation of cancerous white blood cells.
-
Science is compiled in full! Chinese scientists have structurally revealed a powerful therapeutic antibody and SARS-CoV-2 and SARS-CoV mechanisms.
Time of Update: 2020-07-31
of hACE2 to the S protein tripolymer. again, hACE2 can be removed from the S protein tripolymer and replaced by H014 (Figure 3C). in order to further validate these results in a cell-based virus infection model, they performed real-time RT-PCR analysis to quantify residual virus attachment at 4 degrees C.
-
Science: Chinese scientists have structurally revealed a powerful therapeutic antibody and SARS-CoV-2 and SARS-CoV mechanisms.
Time of Update: 2020-07-29
/>!---- The pathogen that led to this pandemic is an emerging coronavirus: SARS-CoV-2, which is closely related to THE SARS-CoV, which belongs to the coronavirus family b lineage The stingy glycoprotein (S) located in the SARS-CoV-2 and SARS-CoV
-
New therapeutic antibodies for coronary pneumonia developed by Institute of Microbiology of Chinese Academy of Sciences enter clinical trials
Time of Update: 2020-06-27
Introduction: This marks the successful entry of the new coronavirus-specific antibody drug with China's independent intellectual property rights into the human clinical evaluation stage June 5, 2020, the State Drug Administration officially
